Semaglutide medications like Ozempic and Wegovy suppress appetite and accelerate weight loss, but experts warn that inadequate protein intake may increase the risk of muscle loss. Here’s why protein has become a major focus for GLP-1 users and how clinicians recommend protecting lean mass during treatment.
GLP-1 medications can make adequate protein intake surprisingly difficult during weight loss. This guide explains the best high-protein Trader Joe’s foods for semaglutide and tirzepatide users trying to preserve muscle, reduce hunger, and simplify nutrition.
GLP-1 medications can dramatically reduce appetite, making adequate protein intake difficult during weight loss. This guide explains the best Costco and Trader Joe’s high-protein foods, snacks, and meal strategies for semaglutide and tirzepatide users trying to preserve muscle while managing nausea and early fullness.
Rapid weight loss from GLP-1 medications like Ozempic and Wegovy may lead to muscle loss and a flattened glute appearance known as “Ozempic butt.” Learn how resistance training, protein intake, and targeted glute exercises can help preserve muscle and support healthier weight loss.
Constipation is a common yet overlooked side effect of GLP-1 medications like semaglutide. Learn why it happens, how to prevent it, and when it may signal something more serious.
Rapid weight loss from GLP-1 medications can accelerate facial aging through volume depletion and collagen loss. This in-depth guide compares Sculptra vs. Radiesse for restoring facial structure, tightening skin, and treating “Ozempic Face.”
Semaglutide may reshape more than appetite—it can influence the brain’s reward system. Here’s what science says about anhedonia and mood changes on GLP-1 drugs.
Hair loss on Wegovy affects a small but notable percentage of users. This expert review explains the science behind shedding, risk factors, and recovery timelines.
GLP-1 weight loss drugs are transforming obesity care—but their high cost raises urgent questions about access, insurance coverage, and long-term sustainability.
Semaglutide and tirzepatide are transforming obesity treatment through hormone-based therapy. Here’s how their mechanisms, outcomes, and risks compare.